ReviewDermatology and therapy2022
New Developing Treatments for Molluscum Contagiosum.
Review in Dermatology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Cutaneous-Tropism Viruses: Unraveling Pathogenetic Mechanisms and Immunoprophylactic Strategies.Life (Basel, Switzerland) · 2026Review
- Beginning of the End (BOTE) Sign in the Setting of Recurrent Molluscum Contagiosum in a Child.Cureus · 2025Article
- Improving Molluscum Treatment Options: Overcoming the Challenge of Poor Adherence.The Journal of clinical and aesthetic dermatology · 2025Review
- Clinical Diagnosis and Novel Treatment of Eyelid Molluscum Contagiosum.Case reports in infectious diseases · 2025Article
- Article
- Berdazimer Topical Gel, 10.3%: First Approval.Drugs · 2024Review
- [Human monkeypox (Mpox)].Dermatologie (Heidelberg, Germany) · 2024Review
- Cantharidin Topical Solution 0.7%: First Approval.Paediatric drugs · 2024Review
- Molluscum contagiosum at eyelid.BMJ case reports · 2023Article
- Berdazimer Sodium: A Novel Nitric Oxide-Releasing Drug in Dermatology.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A large variety of treatments for molluscum contagiosum (MC) are available, but none are Food and Drug Administration (FDA) approved and there is no consensus on the optimal approach, mainly owing to a lack of high-level data. Physical modalities are widely used, but require repeated outpatient visits for administration, are painful and difficult to perform in children, and are associated with the possibility of residual scarring and post-inflammatory hypo- or hyperpigmentation. Two experimental topical drugs, a new standardized preparation of topical cantharidin, called VP-102, and a topical nitric oxide (NO)-releasing product containing berdazimer, called SB206, represent promising products that have been designed to overcome the limitations of current treatments. They have recently shown good results in terms of safety and efficacy in large cohorts of patients in phase III studies and have the potential to be the first FDA-approved therapies for the treatment of MC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.